| Size | Price | Stock |
|---|---|---|
| 100 mg | Get quote | |
| 250 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-18180 |
| M.Wt: | 445.38 |
| Formula: | C21H15F4N5O2 |
| Purity: | >98 % |
| Solubility: |
VEGFR/PDGFR-IN-2 is a VEGFR1/2/3, PDGFRα/β, and Tie-2 tyrosine kinase inhibitor. VEGFR/PDGFR-IN-2 inhibits endothelial tube formation and endothelial migration by blocking VEGF-induced receptor phosphorylation and PDGF-BB signaling, reduces tumor microvessel density, pericyte recruitment, and tumor interstitial fluid pressure, and enhances the antitumor activity of CPT-11. VEGFR/PDGFR-IN-2 can be used for research on solid tumors[1].
In Vitro:VEGFR/PDGFR-IN-2 (compound 20d) (3 days) inhibited the proliferation of cultured cancer cell lines with IC50 values of 3.5-7.2 µM[1].
VEGFR/PDGFR-IN-2 inhibits VEGFR1, VEGFR2, VEGFR3, PDGFRα, PDGFRβ, and Tie-2 kinase activity with IC50 values of 15, 6.2, 10, 35, 96, and 20 nM, respectively[1].
VEGFR/PDGFR-IN-2 (0.064-200 nM; 2 h) inhibits VEGF-induced VEGFR2 phosphorylation in HUVECs and PDGF-BB-induced PDGFRβ phosphorylation in CASMCs, with IC50 values of 2.5 and 3.6 nM, respectively[1].
VEGFR/PDGFR-IN-2 (5 days) inhibits VEGF-stimulated HUVEC proliferation with an IC50 of 2.8 nM[1].
VEGFR/PDGFR-IN-2 (6 days) inhibits PDGF-BB-stimulated CASMC proliferation with an IC50 of 9.6 nM[1].
VEGFR/PDGFR-IN-2 (0.3-10 nM; 7 days) inhibits VEGF-induced tube formation in HUVECs co-cultured with normal human dermal fibroblasts, with an IC50 of 3.3 nM[1].
In Vivo:VEGFR/PDGFR-IN-2 (compound 20d) (1.5-10 mg/kg; oral; twice daily or once daily; 3-21 days) produced dose-dependent antitumor activity in A549 xenograft mice and reduced tumor microvessel density and perivascular pericyte recruitment[1].
VEGFR/PDGFR-IN-2 (1.5-5.0 mg/kg; oral; twice daily; days 2-21) inhibits HT-29 tumor growth and reduces tumor interstitial fluid pressure, enhancing intratumoral uptake of CPT-11 and its active metabolite SN-38[1].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information
Your information is safe with us.